search
Back to results

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin)

Primary Purpose

Solid Tumor, Adult

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
eFT226
Sotorasib
Fulvestrant
Abemaciclib
Trastuzumab
Sponsored by
Effector Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumor, Adult

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Criteria:

Parts 1a and 1b (Dose Escalation + Fulvestrant):

  • Patient has histological or cytological confirmation of breast cancer.
  • Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit.
  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
    • Prior treatment has included a CDK4/6 inhibitor.
  • Tumor is ER+ (defined as ER IHC staining > 0%).

Cohort EMNK:

  • Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate.
  • Tumor has a known KRAS-activating mutation; Patients with KRAS G12C mutations are excluded.

Cohort EMBF:

  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting, which may include combination therapy (eg, with a CDK4/6 inhibitor).
  • Tumor is ER+ (defined as ER IHC staining > 0%) and has FGFR amplification.

Cohort EMBH:

  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Minimum of one line of HER2-directed therapy Note: Prior treatment with CDK4/6 inhibitors is permitted.
  • Tumor is ER+ (defined as ER IHC staining > 0%) and HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+).

Cohort ECNS:

  • Patient has histologically or cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC.
  • Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate. Note: Patients who have declined approved therapy(ies) or who per treating physician are not eligible for approved therapy(ies) (eg, due to intolerance) may be eligible following discussion with the Medical Monitor.
  • Tumor has a known G12C KRAS-activating mutation. Note: Patients who have been previously treated with KRAS-specific therapy are excluded.

Cohort ECBF:

  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
    • Prior treatment has included a CDK4/6 inhibitor.
  • Tumor is ER+ (defined as ER IHC staining > 0%).

Cohort ECBF+A:

  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
  • Tumor is ER+ (defined as ER IHC staining > 0%) and HER2- (defined as absence of HER2 3+ IHC staining and/or absence of FISH+).

Cohort ECBT:

  • Patient has progressed after treatment with at least one approved anti-HER2 agent and has been administered at least one line of chemotherapy.
  • Tumor is HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+). Cohorts EMBF, EMBH, ECBF, ECBF+A: There is no limit on the number of lines of prior endocrine therapies.

Cohort ECBF-D1:

  • Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit.
  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
    • Prior treatment has included a CDK4/6 inhibitor.
  • Tumor is ER+ (defined as ER IHC staining > 0%).
  • Tumor has amplification of Cyclin D1 as determined by next generation sequencing or in situ hybridization.

Sites / Locations

  • University of Southern CaliforniaRecruiting
  • Valkyrie Clinical TrialsRecruiting
  • Hoag Memorial Hospital PresbyterianRecruiting
  • Stanford UniversityRecruiting
  • START MidwestRecruiting
  • Comprehensive Cancer Centers of Nevada
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer CareRecruiting
  • University of Toledo Medical Center
  • MD Anderson Cancer CenterRecruiting
  • New Experimental Therapeutics of San Antonio - NEXT OncologyRecruiting
  • Virginia Cancer SpecialistsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Part 1: Sequential escalation (Completed)

Part 2: Cohort Expansion, Monotherapy, NSCLC, KRAS (EMNK)

Part 2: Cohort Expansion, Monotherapy, Breast, FGFR (EMBF)

Part 2: Cohort Expansion, Monotherapy, Breast, HER2 (EMBH)

Part 2: Cohort Expansion, Combination, Breast, Fulvestrant (ECBF)

Part 2: Cohort Expansion, Combination, NSCLC, Sotorasib (ECNS)

Part 2: Cohort Expansion, Combination, Breast, Fulvestrant+Abemaciclib (ECBF+A)

Part 2: Cohort Expansion, Combination, Breast, Trastuzumab (ECBT)

Part 1a: Dose Escalation, Combination, Breast

Part 1b Dose Escalation, Combination, Breast

Part 2 Cohort Expansion, Combination, Breast, Fulvestrant, Cyclin D1

Arm Description

eFT226 administered IV weekly in 21-day cycles; dose escalated in sequential cohorts after subjects enrolled in a given cohort have completed DLT evaluation period.

Cohort EMNK

Cohort EMBF

Cohort EMBH

Cohort ECBF; Combination therapy partner administered per SOC at the approved dose.

Cohort ECNS; Combination therapy partner administered per SOC at the approved dose.

Cohort ECBF+A; Combination therapy partner administered per SOC at the approved dose.

Cohort ECBT; Combination therapy partner administered per SOC at the approved dose.

eFT226 administered IV weekly in 21-day cycles. Fulvestrant will also be given. Dose escalations per protocol.

eFT226 administered IV every other week in 14-day cycles. Fulvestrant will also be given. Dose escalations per protocol.

ECBF-D1; Combination therapy partner administered per SOC at the approved dose.

Outcomes

Primary Outcome Measures

Parts 1a and 1b: MTD
determined by occurrence of first cycle DLTs within a 3+3 or 3+3+3 clinical trial design
Parts 1a and 1b; incidence of AEs, serious adverse events (SAEs), and DLTs
according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Parts 1a and 1b: RP2D
determined by Incidence and type of DLTs
Parts 1a and 1b: RP2D
determine by Incidence, type, and severity of AEs and SAEs graded as per NCI CTCAE
Part 2: Objective Response Rate- Efficacy
defined as confirmed Complete Response (CR) or Partial Response (PR)
Part 2: (Combination Cohorts) Determine MTD
determined by occurrence of first cycle Dose Limiting Toxicities (DLTs) within the study design
Part 2: (Combination Cohorts) Incidence, type, and severity of AEs and SAEs
via adverse event monitoring
Part 2: (Combination Cohorts) Determine RP2D
determined by incidence and type of DLTs, and incidence, type, and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Part 2: Percent change in tumor dimensions of target lesions- Efficacy
calculated by the percentage change from baseline in the sum of the LD of target lesions
Part 2: Time to Response (TTR)- Efficacy
defined as the interval from the start of study therapy to the first documentation of an objective response
Part 2: Duration of Response (DOR)- Efficacy
defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause

Secondary Outcome Measures

Parts 1a and 1b: Objective response
determined by confirmed CR or PR
Parts 1a and 1b: Percent change in tumor dimensions of target lesions
calculated by the percentage change from baseline in the sum of the LD of target lesions
Parts 1a and 1b: TTR
defined as the interval from the start of study therapy to the first documentation of an objective response
Parts 1a and 1b: DOR
defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause
Parts 1a and 1b: PFS
defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause
Part 2: (Monotherapy and Combination Cohorts) Incidence and severity of AEs, SAEs, and additional safety parameters
via adverse event monitoring
Part 2: Progression Free Survival
defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including area under the plasma concentration-time curve
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including maximum concentration
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including terminal phase rate constant
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including estimated steady-state volume of distribution [Vss]
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including half-life (t½)
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
including total body clearance
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226including terminal state volume of distribution
including terminal state volume of distribution
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226 including terminal phase rate constant
including terminal phase rate constant

Full Information

First Posted
September 10, 2019
Last Updated
September 5, 2023
Sponsor
Effector Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT04092673
Brief Title
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Acronym
Zotatifin
Official Title
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 25, 2019 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
March 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Effector Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Detailed Description
Part 1 (Dose Escalation): Completed; Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) identified Part 1a (Dose Escalation) This cohort will enroll patients with an advanced breast cancer that is refractory or intolerant to SOC therapy. Part 1b (Dose Escalation) This cohort will enroll patients with an advanced breast cancer that is refractory or intolerant to SOC therapy. Part 2 (Expansion Cohort) provides defined expansion cohorts to further explore the safety, pharmacology, and clinical activity of eFT226 monotherapy and in various combinations in subjects with previously treated advanced solid tumor malignancies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor, Adult

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Dose Escalation, 3+3, 3+3+3
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1: Sequential escalation (Completed)
Arm Type
Experimental
Arm Description
eFT226 administered IV weekly in 21-day cycles; dose escalated in sequential cohorts after subjects enrolled in a given cohort have completed DLT evaluation period.
Arm Title
Part 2: Cohort Expansion, Monotherapy, NSCLC, KRAS (EMNK)
Arm Type
Experimental
Arm Description
Cohort EMNK
Arm Title
Part 2: Cohort Expansion, Monotherapy, Breast, FGFR (EMBF)
Arm Type
Experimental
Arm Description
Cohort EMBF
Arm Title
Part 2: Cohort Expansion, Monotherapy, Breast, HER2 (EMBH)
Arm Type
Experimental
Arm Description
Cohort EMBH
Arm Title
Part 2: Cohort Expansion, Combination, Breast, Fulvestrant (ECBF)
Arm Type
Experimental
Arm Description
Cohort ECBF; Combination therapy partner administered per SOC at the approved dose.
Arm Title
Part 2: Cohort Expansion, Combination, NSCLC, Sotorasib (ECNS)
Arm Type
Experimental
Arm Description
Cohort ECNS; Combination therapy partner administered per SOC at the approved dose.
Arm Title
Part 2: Cohort Expansion, Combination, Breast, Fulvestrant+Abemaciclib (ECBF+A)
Arm Type
Experimental
Arm Description
Cohort ECBF+A; Combination therapy partner administered per SOC at the approved dose.
Arm Title
Part 2: Cohort Expansion, Combination, Breast, Trastuzumab (ECBT)
Arm Type
Experimental
Arm Description
Cohort ECBT; Combination therapy partner administered per SOC at the approved dose.
Arm Title
Part 1a: Dose Escalation, Combination, Breast
Arm Type
Experimental
Arm Description
eFT226 administered IV weekly in 21-day cycles. Fulvestrant will also be given. Dose escalations per protocol.
Arm Title
Part 1b Dose Escalation, Combination, Breast
Arm Type
Experimental
Arm Description
eFT226 administered IV every other week in 14-day cycles. Fulvestrant will also be given. Dose escalations per protocol.
Arm Title
Part 2 Cohort Expansion, Combination, Breast, Fulvestrant, Cyclin D1
Arm Type
Experimental
Arm Description
ECBF-D1; Combination therapy partner administered per SOC at the approved dose.
Intervention Type
Drug
Intervention Name(s)
eFT226
Other Intervention Name(s)
Selective translation inhibitor
Intervention Description
eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
Intervention Type
Drug
Intervention Name(s)
Sotorasib
Other Intervention Name(s)
Lumarkus
Intervention Description
Recommended dosage: 960 mg orally once daily
Intervention Type
Drug
Intervention Name(s)
Fulvestrant
Other Intervention Name(s)
Faslodex
Intervention Description
500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
Intervention Type
Drug
Intervention Name(s)
Abemaciclib
Other Intervention Name(s)
Verzenia
Intervention Description
Dose in combination with fulvestrant: 150 mg twice daily
Intervention Type
Drug
Intervention Name(s)
Trastuzumab
Other Intervention Name(s)
Herceptin
Intervention Description
600 mg every 3 weeks
Primary Outcome Measure Information:
Title
Parts 1a and 1b: MTD
Description
determined by occurrence of first cycle DLTs within a 3+3 or 3+3+3 clinical trial design
Time Frame
Through study completion, approximately 12 months
Title
Parts 1a and 1b; incidence of AEs, serious adverse events (SAEs), and DLTs
Description
according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame
Through study completion, approximately 12 months
Title
Parts 1a and 1b: RP2D
Description
determined by Incidence and type of DLTs
Time Frame
Through study completion, approximately 12 months
Title
Parts 1a and 1b: RP2D
Description
determine by Incidence, type, and severity of AEs and SAEs graded as per NCI CTCAE
Time Frame
Through study completion, approximately 12 months
Title
Part 2: Objective Response Rate- Efficacy
Description
defined as confirmed Complete Response (CR) or Partial Response (PR)
Time Frame
Through study completion, approximately 12 months
Title
Part 2: (Combination Cohorts) Determine MTD
Description
determined by occurrence of first cycle Dose Limiting Toxicities (DLTs) within the study design
Time Frame
Through study completion, approximately 12 months
Title
Part 2: (Combination Cohorts) Incidence, type, and severity of AEs and SAEs
Description
via adverse event monitoring
Time Frame
Through study completion, approximately 12 months
Title
Part 2: (Combination Cohorts) Determine RP2D
Description
determined by incidence and type of DLTs, and incidence, type, and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame
Through study completion, approximately 12 months
Title
Part 2: Percent change in tumor dimensions of target lesions- Efficacy
Description
calculated by the percentage change from baseline in the sum of the LD of target lesions
Time Frame
Through study completion, approximately 12 months
Title
Part 2: Time to Response (TTR)- Efficacy
Description
defined as the interval from the start of study therapy to the first documentation of an objective response
Time Frame
Through study completion, approximately 12 months
Title
Part 2: Duration of Response (DOR)- Efficacy
Description
defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause
Time Frame
Through study completion, approximately 12 months
Secondary Outcome Measure Information:
Title
Parts 1a and 1b: Objective response
Description
determined by confirmed CR or PR
Time Frame
Through study completion, approximately 12 months
Title
Parts 1a and 1b: Percent change in tumor dimensions of target lesions
Description
calculated by the percentage change from baseline in the sum of the LD of target lesions
Time Frame
Through study completion, approximately 12 months
Title
Parts 1a and 1b: TTR
Description
defined as the interval from the start of study therapy to the first documentation of an objective response
Time Frame
Through study completion, approximately 12 months
Title
Parts 1a and 1b: DOR
Description
defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause
Time Frame
Through study completion, approximately 12 months
Title
Parts 1a and 1b: PFS
Description
defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause
Time Frame
Through study completion, approximately 12 months
Title
Part 2: (Monotherapy and Combination Cohorts) Incidence and severity of AEs, SAEs, and additional safety parameters
Description
via adverse event monitoring
Time Frame
Through study completion, approximately 12 months
Title
Part 2: Progression Free Survival
Description
defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause
Time Frame
Through study completion, approximately 12 months
Title
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
Description
including area under the plasma concentration-time curve
Time Frame
Through study completion, approximately 12 months
Title
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
Description
including maximum concentration
Time Frame
Through study completion, approximately 12 months
Title
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
Description
including terminal phase rate constant
Time Frame
Through study completion, approximately 12 months
Title
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
Description
including estimated steady-state volume of distribution [Vss]
Time Frame
Through study completion, approximately 12 months
Title
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
Description
including half-life (t½)
Time Frame
Through study completion, approximately 12 months
Title
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226
Description
including total body clearance
Time Frame
Through study completion, approximately 12 months
Title
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226including terminal state volume of distribution
Description
including terminal state volume of distribution
Time Frame
Through study completion, approximately 12 months
Title
Evaluate plasma Pharmacokinetic (PK) parameters of eFT226 including terminal phase rate constant
Description
including terminal phase rate constant
Time Frame
Through study completion, approximately 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Criteria: Parts 1a and 1b (Dose Escalation + Fulvestrant): Patient has histological or cytological confirmation of breast cancer. Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit. Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: Minimum of one prior line of therapy for advanced/metastatic disease. Maximum of five prior lines of therapy for advanced/metastatic disease. Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting. Prior treatment has included a CDK4/6 inhibitor. Tumor is ER+ (defined as ER IHC staining > 0%). Cohort EMNK: Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate. Tumor has a known KRAS-activating mutation; Patients with KRAS G12C mutations are excluded. Cohort EMBF: Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: Minimum of one prior line of therapy for advanced/metastatic disease. Maximum of five prior lines of therapy for advanced/metastatic disease. Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting, which may include combination therapy (eg, with a CDK4/6 inhibitor). Tumor is ER+ (defined as ER IHC staining > 0%) and has FGFR amplification. Cohort EMBH: Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: Minimum of one prior line of therapy for advanced/metastatic disease. Minimum of one line of HER2-directed therapy Note: Prior treatment with CDK4/6 inhibitors is permitted. Tumor is ER+ (defined as ER IHC staining > 0%) and HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+). Cohort ECNS: Patient has histologically or cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC. Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate. Note: Patients who have declined approved therapy(ies) or who per treating physician are not eligible for approved therapy(ies) (eg, due to intolerance) may be eligible following discussion with the Medical Monitor. Tumor has a known G12C KRAS-activating mutation. Note: Patients who have been previously treated with KRAS-specific therapy are excluded. Cohort ECBF: Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: Minimum of one prior line of therapy for advanced/metastatic disease. Maximum of five prior lines of therapy for advanced/metastatic disease. Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting. Prior treatment has included a CDK4/6 inhibitor. Tumor is ER+ (defined as ER IHC staining > 0%). Cohort ECBF+A: Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: Minimum of one prior line of therapy for advanced/metastatic disease. Maximum of five prior lines of therapy for advanced/metastatic disease. Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting. Tumor is ER+ (defined as ER IHC staining > 0%) and HER2- (defined as absence of HER2 3+ IHC staining and/or absence of FISH+). Cohort ECBT: Patient has progressed after treatment with at least one approved anti-HER2 agent and has been administered at least one line of chemotherapy. Tumor is HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+). Cohorts EMBF, EMBH, ECBF, ECBF+A: There is no limit on the number of lines of prior endocrine therapies. Cohort ECBF-D1: Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit. Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows: Minimum of one prior line of therapy for advanced/metastatic disease. Maximum of five prior lines of therapy for advanced/metastatic disease. Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting. Prior treatment has included a CDK4/6 inhibitor. Tumor is ER+ (defined as ER IHC staining > 0%). Tumor has amplification of Cyclin D1 as determined by next generation sequencing or in situ hybridization.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mark Densel
Phone
858-925-8215
Email
clinicaltrials@effector.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Douglas Warner, MD
Organizational Affiliation
EFFECTOR Therapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
University of Southern California
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiomara Menendez
Phone
323-409-4638
Email
menendez_x@med.usc.edu
First Name & Middle Initial & Last Name & Degree
Anthony El-Khoueiry, MD
Facility Name
Valkyrie Clinical Trials
City
Los Angeles
State/Province
California
ZIP/Postal Code
90067
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chemyn Cortez
Phone
559-360-3707
Email
chemyn.cortez@valkyrieclinicaltrials.com
First Name & Middle Initial & Last Name & Degree
David Berz, MD
Facility Name
Hoag Memorial Hospital Presbyterian
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rosie Blancas
Phone
949-764-5543
Email
Rosie.Blancas1@hoag.org
First Name & Middle Initial & Last Name & Degree
Anthony El-Khouiery, MD
Facility Name
Stanford University
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kaushali Thakore-Shah
Email
kthakore@stanford.edu
First Name & Middle Initial & Last Name & Degree
Jennifer Caswell-Jin, MD
Facility Name
START Midwest
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49546
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jade Blakeman
Phone
616-954-5551
Email
Jade.Blakeman@startmidwest.com
First Name & Middle Initial & Last Name & Degree
Manish Sharma, MD
Facility Name
Comprehensive Cancer Centers of Nevada
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89169
Country
United States
Individual Site Status
Completed
Facility Name
Memorial Sloan Kettering Cancer Center
City
Middletown
State/Province
New Jersey
ZIP/Postal Code
07748
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ezra Rosen
Email
rosene1@mskcc.org
First Name & Middle Initial & Last Name & Degree
Colleen Wenzel
Email
WenzelC1@mskcc.org
First Name & Middle Initial & Last Name & Degree
Ezra Rosen, MD
Facility Name
Memorial Sloan Kettering Cancer Center
City
Commack
State/Province
New York
ZIP/Postal Code
11725
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ezra Rosen, MD
Email
rosene1@mskcc.org
First Name & Middle Initial & Last Name & Degree
Colleen Wenzel
Email
WenzelC1@mskcc.org
First Name & Middle Initial & Last Name & Degree
Ezra Rosen, MD
Facility Name
Memorial Sloan Kettering Cancer Center
City
Harrison
State/Province
New York
ZIP/Postal Code
10604
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ezra Rosen
Email
rosene1@mskcc.org
First Name & Middle Initial & Last Name & Degree
Colleen Wenzel
Email
WenzelC1@mskcc.org
First Name & Middle Initial & Last Name & Degree
Ezra Rosen, MD
Facility Name
Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care
City
New York
State/Province
New York
ZIP/Postal Code
11101
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ezra Rosen, MD
Email
rosene1@mskcc.org
First Name & Middle Initial & Last Name & Degree
Colleen Wenzel
Email
WenzelC1@mskcc.org
First Name & Middle Initial & Last Name & Degree
Ezra Rosen, MD
Facility Name
University of Toledo Medical Center
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43614
Country
United States
Individual Site Status
Completed
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Ekert
Phone
713-745-8074
Email
ACEckert@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Funda Meric-Bernstam, MD
Facility Name
New Experimental Therapeutics of San Antonio - NEXT Oncology
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Klein
Phone
210-580-9543
Email
nklein@nextoncology.com
First Name & Middle Initial & Last Name & Degree
David Sommerhalder, MD
Facility Name
Virginia Cancer Specialists
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karina Castillo-Grady
Phone
703-280-5390
Email
Karina.CastilloGrady@usoncology.com
First Name & Middle Initial & Last Name & Degree
Alexander Spira, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is not a plan to make IPD available

Learn more about this trial

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

We'll reach out to this number within 24 hrs